L-Methyl Dopa
Brand names,
L-Methyl Dopa
Analogs
L-Methyl Dopa
Brand Names Mixture
L-Methyl Dopa
Chemical_Formula
C56H71N9O23S
L-Methyl Dopa
RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
L-Methyl Dopa
fda sheet
L-Methyl Dopa
msds (material safety sheet)
L-Methyl Dopa
Synthesis Reference
No information avaliable
L-Methyl Dopa
Molecular Weight
1270.28 g/mol
L-Methyl Dopa
Melting Point
No information avaliable
L-Methyl Dopa
H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
L-Methyl Dopa
State
Solid
L-Methyl Dopa
LogP
No information avaliable
L-Methyl Dopa
Dosage Forms
Powder for solution (for injection)
L-Methyl Dopa
Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
L-Methyl Dopa
Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
L-Methyl Dopa
Absorption
No information avaliable
L-Methyl Dopa
side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
L-Methyl Dopa
Patient Information
No information avaliable
L-Methyl Dopa
Organisms Affected
Aspergillis, Candida and other fungi